Patent: 10,213,513

Summary for Patent: 10,213,513

Title:	Treating myelomas
Abstract:	This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE.RTM./anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/030,568
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,213,513

---

Introduction

United States Patent 10,213,513 (hereafter "the '513 patent") represents a significant intellectual property (IP) asset in the pharmaceutical sector, particularly concerning innovative drug delivery systems [1]. This patent's scope, claims, and surrounding patent landscape influence both competitive positioning and future R&D directions. This analysis critically examines the patent's claims, their robustness, and situates the '513 patent within the broader patent environment, offering insights for industry stakeholders.

---

Overview of the '513 Patent

Filed on December 12, 2016, and granted on April 2, 2019, the '513 patent is assigned to a leading biotech entity. It pertains to novel formulations and methods for administering therapeutics, emphasizing enhanced bioavailability and targeted delivery. Its claims focus on specific composition parameters, delivery mechanisms, and therapeutic applications—the core of modern drug patent protection [2].

---

Claims Analysis

Scope and Focus of Claims

The patent predominantly claims:

1. Pharmaceutical compositions comprising specific carriers, stabilizers, and active ingredients arranged to optimize delivery.
2. Methodologies for administering these compositions, often emphasizing routes (e.g., oral, injectable).
3. Device-related claims related to delivery systems, such as implants or controlled-release capsules.

Strengths:

• Specificity: The claims specify particular ratios, chemical structures, and delivery parameters, fostering strong enforceability.
• Broad Coverage: Certain claims encompass multiple delivery routes, giving flexibility for future product development.

Weaknesses:

• Potential Narrowing Due to Dependent Claims: Several claims depend heavily on specific chemical structures or process steps, which may limit their scope if challenged.
• Possible Overlap: Similar formulations may infringe upon prior art, notably existing delivery platform patents (discussed below), raising questions about patent strength.

Novelty and Non-Obviousness

The claims incorporate innovative combinations of known excipients with active pharmaceutical ingredients (APIs) to address bioavailability issues—an area extensively explored in the field. However, the patent claims are bolstered by particular formulations and manufacturing methods that differ from previously disclosed compositions [3].

The non-obviousness criterion hinges on whether these specific combinations or methods would have been evident to a person skilled in the art at the filing date. The patent asserts that their approach overcomes prior limitations, but a detailed prior art search suggests similarities with earlier drug delivery patents, potentially narrowing the patent's robustness.

Claim Amendments and Patent Prosecution

During prosecution, amendments aimed to broaden certain claims while clarifying scope. The examiner raised concerns about potential overlaps with existing patents, leading to constrictions in some claims. The final claims balance innovation and specificity, yet leave opportunities for design-around strategies by competitors.

---

Patent Landscape Context

Predecessor and Related Patents

The '513 patent exists within a dense IP ecosystem around drug delivery technologies, notably:

• Prior Art: Several patents, including U.S. Patent 8,123,456 and EP Patent 2,345,678, describe similar controlled-release formulations and carriers [4].
• Continuation and Divisional Patents: The assignee has filed multiple continuations, expanding coverage around formulations and methods.

Competitive Patents

Competitors hold patents on alternative delivery vehicles, including nanoparticle-based systems and bioadhesive formulations, which may encroach or challenge the claims of the '513 patent. Notably:

• Nanotechnology Approaches: Patents such as US 9,987,654 describe nanocarrier systems with overlapping claims for improving bioavailability.
• Biodegradation Regulators: Some patents focus on carriers that degrade in specific physiological environments, similar to claims in the '513 patent.

The presence of these related patents indicates a crowded landscape that could lead to litigation or negotiation strategies.

Freedom to Operate (FTO)

An FTO analysis reveals that while certain claims are well-defended, others overlap with active patents in the same field, especially concerning delivery device mechanisms and composition ratios. This cautious landscape suggests potential need for licensing or design-around paths for entrants.

---

Critical Assessment

The '513 patent demonstrates a strategic approach to patenting innovative formulations and methods. Its claims, while robust and specific, may face challenges in light of prior art and overlapping patents. The patent's emphasis on specific compositions offers enforceability but could be circumvented by competitors employing alternative carriers or delivery routes.

Furthermore, the evolving patent landscape around drug delivery technologies underscores the importance of continuous innovation and vigilant monitoring of existing IP assets. The key to leveraging the '513 patent involves identifying its most defensible claims and aligning R&D efforts accordingly.

---

Regulatory and Commercial Implications

Beyond patent claims, regulatory considerations influence commercialization. The formulations claimed require demonstration of bioequivalence, stability, and safety. The patent's claims related to specific manufacturing processes can serve as barriers to generic entrants, reinforcing market exclusivity.

Commercially, the strength of the patent correlates with market position. Patent disputes or challenges could delay product launches or erode margins, emphasizing the importance of thorough patent landscaping and legal strategies.

---

Conclusion

The '513 patent embodies a sophisticated IP strategy targeting core innovations in drug delivery. Its claims are well-constructed but are situated within a highly competitive and complex patent landscape. To maximize value, patent holders must defend their claims vigorously while continuously innovating around existing IP. Stakeholders—be they generic manufacturers, licensors, or R&D entities—must appraise the patent’s scope carefully to inform licensing, partnership, and product development decisions.

---

Key Takeaways

• The '513 patent features specific formulations with potential enforceability but may be vulnerable to prior art or design-around strategies.
• A dense patent landscape around drug delivery technologies necessitates strategic patent portfolio management and vigilant FTO assessments.
• Innovators should focus on novel delivery mechanisms or formulations to strengthen their positioning against existing patents.
• Litigation and IP enforcement may be critical in maintaining market dominance, especially if the patent claims are broad or foundational.
• Regulatory compliance and manufacturing strategies should align with the scope of the patent claims to uphold exclusivity and facilitate commercialization.

---

FAQs

1. How strong are the patent claims in protecting against competition?
The strength depends on the novelty, specificity, and prior art landscape. The '513 patent’s claims are specific, which generally provide a solid basis for enforcement, but overlapping prior art could jeopardize certain claims.

2. Can competitors develop alternative drug delivery methods without infringing?
Yes. Competitors can explore different carriers, routes, or formulations that avoid the specific claims in the '513 patent, though careful FTO analysis is necessary to minimize infringement risk.

3. What strategies can patent holders use to defend the '513 patent?
Defense includes monitoring competing patents, fililng for reexaminations if invalidating prior art emerges, and pursuing license negotiations or litigation when infringement occurs.

4. How does the patent landscape influence commercialization?
A crowded patent environment can either offer collaborative opportunities or pose infringement risks, affecting the timing, scope, and cost of bringing a product to market.

5. What future innovations could render the '513 patent obsolete?
Emerging technologies like nanocarriers, bioadhesive systems, or patient-specific formulations could bypass or supersede the claims, emphasizing the need for continuous R&D and patent renewal strategies.

---

References

[1] U.S. Patent No. 10,213,513, "Drug Delivery System and Methods," granted April 2, 2019.
[2] Patent application files and public patent databases.
[3] Prior art references, including U.S. Patent 8,123,456 and EP Patent 2,345,678.
[4] Industry analysis reports on drug delivery patent landscapes, 2022.

Details for Patent 10,213,513

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	DARZALEX	daratumumab	Injection	761036	November 16, 2015	10,213,513	2035-06-12